Cell therapy for cardiac repair through mobilization of hematopoietic stem cells and endothelial progenitors in patients with chronic ischemic cardiomyopathy. - NA
- Conditions
- Chronic ischemic cardiac disease
- Registration Number
- EUCTR2004-004545-18-BE
- Lead Sponsor
- CHU Sart Tilman
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 24
- Stable chronic ischemic cardiopathy
- Optimal drug treatment
- No possible cardiac surgery or angioplasty
- NYHA class II-IV
- Left ventricular ejection fraction <40%
- Collateral circulation and/or hibernating myocardium
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
- Inclusion criteria not fully met
- Previous neoplasia (except in situ cervical cancer or non-melanoma skin cancer)
- HIV, HBsAg or HC positive status
- Hematological condition potentially impairing response to haematopoietic growth factors
- Active infection or inflammatory disorder
- Uncontrolled hypertension
- Allergy to G-CSF or EPO
- Hb >16 g/dl
- Blood transfusion dependance
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method